

CIMT.EU

Annual Report

2022





Annual Report 2022



/

Dear CIMT Members, Supporters, and Friends,

I am pleased to present our 2023 annual report, marking two incredible decades since the establishment of CIMT in 2002.

We celebrated the 20th anniversary of the Association with a return to our on-site Annual Meeting after two years of social distancing. It was wonderful to see the international research community coming back together and fostering a spirit of collaboration and innovation.

It was with profound gratitude that I accepted the trust of the CIMT members in my continued leadership as the reelected President of this impactful association. I accept your vote of confidence as a testament to our shared commitment and pursuit of progress in the realm of cancer immunotherapy.

A highlight of our year was the Summer School in Illasi, Italy. This engaging three-day event, especially dedicated to young scientists, signified our dedication to inspiring the next generation of trailblazers in our field.

None of this would be possible without our sponsors and supporters. Your generosity and commitment in 2022 have bolstered our mission, enabling us to make remarkable strides in the face of this global health challenge.

As we forge ahead, let us celebrate our achievements, remain hopeful for the future, and continue working together towards our goal of developing efficacious immune-based treatment options for all cancers.

Thank you for being part of our journey.

Sincerely,

Özlem Türeci, M.D.
CIMT President

/ CIMT BOARD ELECTIONS

After two years in which the annual Members Meeting could not be held in person, the members gathered at the Rheingoldhalle Conference Center on May 11, 2022, to discuss the Association's latest and future activities and to vote on the re-election or election of several members of the Executive Board since their three-year term of office had ended.

The following Board members were re-elected for another three-year term of office: **Özlem TÜreci** as President of the Association; **Michael Föhlings** as Treasurer of the Association; **Christoph Huber** and **Johanna Olweus** as regular members of the Board; and CIMT Program Director **Mustafa Diken** as a new member of the Board.



The CIMT Board



Özlem TÜreci
President



Kees Melief
Vice President



Carl Figdor
Secretary



Christoph Huber



Michael Föhlings
Treasurer



Sebastian Kreiter



Mustafa Diken



Johanna Olweus



The CIMT Management Team



Christine Castle
Managing Director



Jan David Beck



Christiane Wellié-Reeve

/ LETTER FROM THE CIMT MANAGING DIRECTOR

Returning to an on-site CIMT Annual Meeting was a milestone in 2022. It was a joy to host the CIMT community again after two years of social distancing and remote meetings. Even with COVID mask mandates still in place, the participants' delight to again experience face-to-face scientific exchange was evident. Over 700 participants attended the meeting on-site and an additional 200 participants took advantage of following the livestream. We were happy to offer this remote participation option for the 2022 Annual Meeting but also felt the considerable financial resources it took to organize a hybrid meeting.

As a not-for-profit organization we use every cent to support our educational programs. Our small staff was able to navigate the choppy waters in the wake of the COVID pandemic: cutting activities in 2020 without losing our infrastructure, re-inventing the CIMT Annual Meeting as an online conference in 2021, and offering a hybrid conference experience in 2022. I would like to thank our corporate sponsors who have supported our programs. Without their support CIMT would not be able to subsidize the participation of the students and postdocs who contribute so much energy and new research to our meetings. For over 10 years, CIMT has sponsored the attendance of early-career researchers who otherwise would not have been able to attend the CIMT Annual Meeting. These travel awards not only support individual researchers from underrepresented countries but also further connect the research community internationally.

In 2022, we also continued our CIMT Academy, providing early-career translational cancer researchers an extraordinary development experience among peers and leaders in an extraordinary setting. In collaboration with the Università di Verona PhD School in Life and Health Sciences and NIBIT, CIMT hosted its first Summer School in Illasi, Italy. The beautiful weather and location contributed to the relaxed atmosphere of this three-day retreat that allowed for extensive group and one-on-one scientific discussions. It also forged personal connections between participants who attended from 14 countries. After spending months arranging the Academy, it was an



absolute pleasure to personally attend the event and facilitate the on-site activities.

In addition to its Annual Meeting and Academy, CIMT is also active in the European Network for Cancer Immunotherapy which connects several European dedicated tumor immunology associations. As the ENCI coordinator, I am pleased to collaborate on the International Cancer Immunotherapy Conference series together with the American Association for Cancer Research and the Cancer Research Institute, in New York City in 2022 and back in Europe in Milan in September of 2023.

In 2023, CIMT will celebrate its 20th Annual Meeting and return to an on-site only forum. Together with our program committee and our board, the CIMT administrative team is excited to organize and run inspiring conferences and meetings that connect the scientific community.

Yours cordially,

Christine Castle

20 YEARS OF CIMT



2002 Founding year

In October of 2002, Prof. Christoph Huber, then head of the department of hematology at Johannes Gutenberg University Medical Center, founded the Association together with a group of leading clinical and theoretical immunologists, oncologists and hematologists from Mainz, Berlin, Erlangen, and Tübingen. The goal of the Association was "to promote and conduct scientific conferences, basic scientific research, therapy studies and research cooperations in the field of immunotherapy of malignant diseases."

2003 First CIMT Annual Meeting

Since 2003, the CIMT Annual Meeting has connected the global cancer immunotherapy community in the heart of Europe. As the largest science-driven, not-for-profit event in Europe focusing on cancer immunology and immunotherapy, CIMT has fostered the development of immunotherapies by offering a platform addressing the latest advances, successes, and challenges in the field.



2005 CIMT Immunoguiding Program CIP

In 2005, the CIMT Immunoguiding Program CIP was founded to guide the development of innovative cancer immunotherapeutics through inter-laboratory harmonization and quality control education. The working group co-organizes dedicated immunoguiding sessions at the CIMT Annual Meeting and other conferences.

2008 Regulatory Research Group RRG

In 2008, the CIMT Regulatory Research Group was founded as an independent group of experts focusing on regulatory aspects of drug development. The group discusses the generic principles and publicly available information on national and international laws, directives and regulations influencing the development of immunotherapy.



2012 10-year Anniversary Meeting

With an outstanding lineup of internationally renowned speakers and record numbers of new scientific contributions by international participants from academia and industry, the 10th Anniversary Meeting was celebrated as the premier European meeting dedicated to research and development of cancer immunotherapy.

2017 First CIMT Lifetime Achievement Award and CICON

At a celebratory Anniversary Symposium for CIMT members and friends of the Association in May of 2017, Prof. Kees Melief was honored with the First CIMT Lifetime Achievement Award. In September, the CICON meeting collaboration with AACR and CRI which began in 2015 came to Mainz. CICON 2017 welcomed over 1400 attendees from 41 countries to Rheingoldhalle Congress Center.



2019 Özlem Türeci elected CIMT President

Stepping down after more than 17 years, Christoph Huber handed over CIMT leadership to Dr. Özlem Türeci. Özlem Türeci was unanimously elected the new CIMT President. Dr. Türeci had been a CIMT board member for the previous seven years.



2021 Virtual CIMT Meeting

Because of the COVID-19 pandemic, the largest European meeting focused on cancer immunotherapy research and development was held in a virtual format. Over 800 academic and clinical professionals in the fields of tumor immunology were attending online. Over 220 submitted abstracts were presented online as eTalks.



MILESTONE PUBLICATIONS IN CANCER IMMUNOTHERAPY 2002 - 2022

20 YEARS OF DISCOVERIES

Since the Association for Cancer Immunotherapy was founded in 2002, hundreds of scientific papers have documented the discoveries and advancements in cancer immunology.

In collaboration with Accelerating Cancer Immunotherapy Research (ACIR), CIMT identified a selection of seminal research papers published in the last 20 years that have made a lasting impact.

The selection also puts a special focus on the CIMT community. We have highlighted all scientists who have come to the CIMT Annual Meeting within the last 20 years to present their work.

2002

Cancer immunoediting- from immunosurveillance to tumor escape

Gavin P Dunn, Allen T Bruce, Hiroaki Ikeda, Lloyd J Old, [Robert D Schreiber](#)
Nature Immunology. 2002.

2003

Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

A Löffler, M Gruen, C Wuchter, F Schriever, P Kufer, T Dreier, F Hanakam, [P A Baeuerle](#), K Bommert, L Karawajew, B Dörken, [R C Bargou](#)
Leukemia. 2003.

2004

Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy

Tobias Krüger, Oliver Schoor, Claudia Lemmel, Bjoern Kraemer, Christian Reichle, Jörn Dengjel, Toni Weinschenk, Margret Müller, Jörg Hennenlotter, Arnulf Stenzl, [Hans-Georg Rammensee](#), [Stefan Stevanović](#)
Cancer Immunology Immunotherapy. 2004.

2005

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

Noelia Casares, Marie O Pequignot, [Antoine Tesniere](#), François Ghiringhelli, Stéphan Roux, Nathalie Chaput, Elise Schmitt, Ahmed Hamai, Sandra Hervas-Stubbs, Michel Obeid, Frédéric Coutant, Didier Métivier, Evelyne Pichard, Pierre Aucouturier, Gérard Pierron, Carmen Garrido, [Laurence Zitvogel](#), [Guido Kroemer](#)
The Journal of Experimental Medicine. 2005.

The response of autologous T cells to a human melanoma is dominated by mutated antigens

Volker Lennerz, Martina Fatho, Chiara Gentilini, Roy A Frye, Alexander Lifke, Dorothea Ferel, Catherine Wölfel, [Christoph Huber](#), [Thomas Wölfel](#)
Proc Natl Acad Sci USA. 2005.

2006

Design and use of conditional MHC class I ligands

Mireille Toebes, Miriam Coccors, Adriaan Bins, Boris Rodenko, Raquel Gomez, Nella J Nieuwkoop, Willeke van de Kastele, Guus F Rimmelzwaan, [John B A G Haanen](#), Huib Ovaa, [Ton N M Schumacher](#)
Nature Medicine. 2006.

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

[Jérôme Galon](#), Anne Costes, Fatima Sanchez-Cabo, Amos Kirilovsky, Bernhard Mlecnik, Christine Lagorce-Pagès, Marie Tosolini, Matthieu Camus, Anne Berger, Philippe Wind, Franck Zinzindohoué, Patrick Bruneval, Paul-Henri Cugnenc, [Zlatko Trajanoski](#), [Wolf-Herman Fridman](#), Franck Pagès
Science. 2006.

2007

Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection

[E John Wherry](#), Sang-Jun Ha, [Susan M Kaech](#), W Nicholas Haining, Surojit Sarkar, Vandana Kalia, Shruti Subramaniam, Joseph N Blattman, Daniel L Barber, [Rafi Ahmed](#)
Immunity. 2007.

2008

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

Gemma G Kenter, [Marij J P Welters](#), A Rob P M Valentijn, Margriet J G Lowik, Dorien M A Berends-van der Meer, Annelies P G Vloon, Jan W Drijfhout, Amon R Wafelman, Jaap Oostendorp, Gert Jan Fleuren, [Rienk Offringa](#), [Sjoerd H van der Burg](#), [Cornelis J M Melief](#)
Clinical Cancer Research. 2008.

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network
Nature. 2008.

2010

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

[F Stephen Hodi](#), Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, [John B Haanen](#), Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel, Wallace Akterley, Alfons J M van den Eertwegh, Jose Lutzky, Paul Lorigan, Julia M Vaubel, Gerald P Linette, David Hogg, [Christian H Ottensmeier](#), Celeste Lebbé, Christian Peschel, Ian Quirt, Joseph I Clark, [Jedd D Wolchok](#), Jeffrey S Weber, Jason Tian, Michael J Yellin, Geoffrey M Nichol, [Axel Hoos](#), Walter J Urba
New England Journal of Medicine. 2010.

2011

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

[Michael Kalos](#), [Bruce L Levine](#), David L Porter, Sharyn Katz, Stephan A Grupp, Adam Bagg, [Carl H June](#)
Science Translational Medicine. 2011.

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy

Steven A Rosenberg, James C Yang, Richard M Sherry, Udai S Kammula, Marybeth S Hughes, Giao Q Phan, Deborah E Citrin, [Nicholas P Restifo](#), [Paul F Robbins](#), John R Wunderlich, Kathleen E Morton, Carolyn M Laurencot, Seth M Steinberg, Donald E White, [Mark E Dudley](#)
Clinical Cancer Research. 2011.

2012

Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer

Suzanne L Topalian, [F Stephen Hodi](#), Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins, Philip D Leming, David R Spigel, Scott J Antonia, Leora Horn, [Charles G Drake](#), [Drew M Pardoll](#), Lieping Chen, William H Sharfman, Robert A Anders, Janis M Taube, Tracee L McMiller, Haiying Xu, [Alan J Korman](#), Maria Jure-Kunkel, Shruti Agrawal, Daniel McDonald, Georgia D Kollia, Ashok Gupta, Jon M Wigginton, Mario Sznol
New England Journal of Medicine. 2012.

Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer

Julie R Brahmer, Scott S Tykodi, Laura Q M Chow, Wen-Jen Hwu, Suzanne L Topalian, [Patrick Hwu](#), [Charles G Drake](#), Luis H Camacho, John Kauh, Kunle Odunsi, Henry C Pitot, Omid Hamid, Shailender Bhatia, Renato Martins, Keith Eaton, Shuming Chen, Theresa M Salay, Suresh Alaparthi, Joseph F Grosso, [Alan J Korman](#), Susan M Parker, Shruti Agrawal, Stacie M Goldberg, [Drew M Pardoll](#), Ashok Gupta, Jon M Wigginton
New England Journal of Medicine. 2012.

Exploiting the Mutanome for Tumor Vaccination

[John C Castle](#), [Sebastian Kreiter](#), Jan Diekmann, Martin Löwer, Niels van de Roemer, Jos de Graaf, Abderraouf Selmi, Mustafa Diken, Sebastian Boegel, Claudia Paret, Michael Koslowski, Andreas N Kuhn, [Cedrik M Britten](#), [Christoph Huber](#), [Özlem Türeci](#), [Ugur Sahin](#)
Cancer Research. 2012.

2013

Oncology Meets Immunology: the Cancer-Immunity Cycle

Daniel S Chen, [Ira Mellman](#)
Immunity. 2013.

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

Noriho Iida, Amiran Dzutsev, C Andrew Stewart, [Francesco M Marincola](#), Loretta Smith, Nicolas Bouladoux, Rebecca A Weingarten, Daniel A Molina, Rosalba Salcedo, Timothy Back, Sarah Cramer, Ren-Ming Dai, Hui Kiu, Marco Cardone, Shruti Naik, Anil K Patri, Ena Wang, [Francesco M Marincola](#), Karen M Frank, Yasmine Belkaid, [Giorgio Trinchieri](#), Romina S Goldszmid
Science. 2013.

2014

Linking T-cell receptor sequence to functional phenotype at the single-cell level

Han A, Glanville J, Hansmann L, [Davis MM](#).
Nature Biotechnology. 2014.

2016

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

[Zaretsky JM](#), Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeq PC, [Schumacher TN](#), Lo RS, [Ribas A](#).
New England Journal of Medicine. 2016.

2017

An immunogenic personal neoantigen cancer vaccine for patients with melanoma

[Ott PA](#), Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaippan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberger D, Ritz J, Lander ES, Fritsch EF, [Hacohen N](#), [Wu C](#).
Nature. 2017.

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

[Ugur Sahin](#), Evelyn Derhovanessian, Matthias Miller, Björn-Philipp Kloke, Petra Simon, Martin Löwer, Valesca Bukur, Arbel D Tadmor, Ulrich Luxemburger, Barbara Schrörs, Tana Omokoko, Mathias Vormehr, Christian Albrecht, Anna Paruzynski, Andreas N Kuhn, Janina Buck, Sandra Heesch, Katharina H Schreeb, Felicitas Müller, Inga Ortseifer, Isabel Vogler, Eva Godehardt, Sebastian Attig, Richard Rae, Andrea Breitkreuz, Claudia Tolliver, Martin Suchan, Goran Martic, Alexander Hohberger, Patrick Sorn, Jan Diekmann, Janko Ciesla, Olga Waksman, Alexandra-Kemmer Brück, Meike Witt, Martina Zillgen, Andree Rothermel, Barbara Kasemann, David Langer, Stefanie Bolte, Mustafa Diken, [Sebastian Kreiter](#), Romina Nemecek, Christoffer Gebhardt, [Stephan Grabbe](#), Christoph Höller, Jochen Utikal, [Christoph Huber](#), Carmen Loquai, [Özlem Türeci](#).
Nature. 2017.

2018

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

Janos L Tanyi, Sara Bobisse, Eran Ophir, Sandra Tuyaerts, Annalisa Roberti, Raphael Genolet, Petra Baumgartner, Brian J Stevenson, Christian Iseli, Denarda Dangaj, Brian Czerniecki, Aikaterini Semilietof, Julien Racle, Alexandra Michel, Ioannis Xenarios, Cheryl Chiang, Dimitri S Monos, Drew A Torigian, Harvey L Nisenbaum, Olivier Michielin, [Carl H June](#), [Bruce L Levine](#), Daniel J Powell Jr, David Gfeller, Rosemarie Mick, Urania Dafni, Vincent Zoete, Alexandre Harari, [George Coukos](#), Lana E Kandalaft.
Science Translational Medicine. 2018.

2019

MHC-II neoantigens shape tumour immunity and response to immunotherapy

Elise Alspach, Danielle M Lussier, Alexander P Miceli, Ilya Kizhvatov, Michel DuPage, Adrienne M Luoma, Wei Meng, Cheryl F Licht, Ekaterina Esaulova, Anthony N Vomund, Daniele Runci, Jeffrey P Ward, Matthew M Gubin, Ruan F V Medrano, Cora D Arthur, J Michael White, Kathleen C F Sheehan, Alex Chen, Kai W Wucherpfennig, Tyler Jacks, Emil R Unanue, Maxim N Artyomov, [Robert D Schreiber](#).
Nature. 2019.

2022

GD-2 CART cell therapy for H3K27M-mutated diffuse midline gliomas

[Robbie G Majzner](#), Sneha Ramakrishna, Kristen W Yeom, Shabnum Patel, Harshini Chinnasamy, Liora M Schultz, Rebecca M Richards, Li Jiang, Valentin Barsan, Rebecca Mancusi, Anna C Geraghty, Zinaida Good, Aaron Y Mochizuki, Shawn M Gillespie, Angus Martin Shaw Toland, Jasia Mahdi, Agnes Reschke, Esther H Nie, Isabelle J Chau, Maria Caterina Rotiroti, Christopher W Mount, Christina Baggott, Sharon Mavroukakis, Emily Egeler, Jennifer Moon, Courtney Erickson, Sean Green, Michael Kunicki, Michelle Fujimoto, Zach Ehlinger, Warren Reynolds, Sreevidya Kurra, Katherine E Warren, Snehit Prabhu, Hannes Vogel, Lindsey Rasmussen, Timothy T Cornell, Sonia Partap, Paul G Fisher 6, Cynthia J Campen 6, Mariella G Filbin 5, Gerald Grant 10, Bita Sahaf 1 2, Kara L Davis, Steven A Feldman, [Crystal L Mackall](#), [Michelle Monje](#).
Nature. 2022.



Accelerating Cancer Immunotherapy Research

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.



CONNECTING THE COMMUNITY
SINCE 2002

2022 CIMT Annual Meeting

Europe's Cancer
Immunotherapy Meeting




/ 2022 CIMT ANNUAL MEETING

For the first time after two years, the CIMT Annual Meeting once again took place as an in-person meeting at the Rheingoldhalle Conference Center from May 10 to 12, 2022. CIMT also offered livestream participation in order to allow participants not able to come to Mainz access to the scientific sessions. 211 livestream registrations and 686 on-site registrations evidence the need to provide both options to national and international audiences. The more than 800 participants came from 28 countries. Overall, the scientific content of the online meeting was rated excellent or very good by 94% of all participants. 93% of all participants also said that they would visit another meeting.

193 abstracts were submitted in the following six categories: Therapeutic Vaccination, New Targets and New Leads, Therapeutic Vaccination, New Targets and New Leads, Improving Immunity, Cellular Therapy, Immunomonitoring, Cellular Therapy, Tumor Biology and Interaction with the Immune System, and Improving Immunity.



Again presenting live
and on site



The poster exhibit



/

2022 PLENARY SPEAKERS

Plenary Session 1: Improving Immunity



Megan Burger

Koch Institute at MIT/USA

“Antigen dominance hierarchies shape anti-tumor T-cell phenotypes and immune-therapy response”



Alena Gros Vidal

Val d’Hebron Institute of Oncology/Spain

“Refining the identification of personalized tumor-reactive lymphocytes”



Jolanda de Vries

Radboud University Medical Center/The Netherlands

“Immune modulation in cancer patients”

Corporate Supported Symposium

“Translating science into care in immune-oncology”



Halvard Böniig

University Hospital Frankfurt/Germany

“Evolving T-cell-based therapy”



Peter Schirmacher

University Hospital Heidelberg/Germany

“Personalized immuno-oncology therapy”



Peter Brossart

University Hospital Bonn/Germany

“Advancing the clinical treatment landscape in immune-oncology”

Plenary Session 2: Tumor Microenvironment



Michele de Palma

École Polytechnique Fédérale de Lausanne (EPFL)/Switzerland

“Microenvironmental regulation of tumor response to immune checkpoint blockade”



Robbie Majzner

Stanford University School of Medicine/USA

“Immunotherapy platforms for solid tumors”



Dmitry Gabrilovich

AstraZeneca/USA

“Targeting of myeloid derived suppressor cells in cancer, lessons learned from preclinical studies”

Keynote lecture



Douglas Hanahan

Ludwig Institute for Cancer Research/Switzerland

“Hallmarks of cancer: the immune dichotomy”

Plenary Session 3: Novel Targets



Mads Hald Andersen

National Center for Cancer Immune Therapy/Denmark

“Immune modulatory vaccines in cancer therapy”



Andrew Sewell

Cardiff University/UK

“New models of T-cell recognition and novel broadly-expressed T-cell epitopes by dissection of cancer immunotherapy success”



Kelly Smith

Johns Hopkins Medicine/USA

“Discovering mechanisms of response and resistance to checkpoint blockade using integrated immunogenomics”

Plenary Session 4: Immunometabolism



Martina Seiffert

German Cancer Research Center (DKFZ)/Germany
 "A novel role of IL-10 in maintaining anti-tumor immunity"



Shiladitya Sengupta

Brigham and Women's Hospital/USA
 "Beyond the classical T-cell immune checkpoint inhibitors"



Lydia Dyck

Max Delbrück Center for Molecular Medicine/Germany
 "Obesity suppresses anti-tumor immunity"

Plenary Session 5: Novel Immunoanalytics



Ali Ertürk

Helmholtz Zentrum München/Germany
 "AI-based maging and molecular methods for personalized medicine"



Daniela Thommen

Netherlands Cancer Institute/The Netherlands
 "Dissecting and modulating reactive anti-tumor immunity in patient-derived tumor fragments"



Daniel Schraivogel

European Molecular Biology Laboratory (EMBL)/Germany
 "High-speed fluorescence image-enabled cell sorting"

Company Seminar



Sophia Lollies

Miltenyi Biotec/Germany
 "From gene-editing manufacturing to analytics: the complete clinical T-cell workflow"

Special Session: Chemical Immunology



Dan Peer

Tel Aviv University/Israel
 "RNA therapeutics is going beyond the liver"



Helena Florindo

University of Lisbon/Portugal
 "Regulation of solid tumors immunity using nanotechnology"

Plenary Session 6: Cellular Therapy



Andreas Mackensen

University Hospital Erlangen/Germany
 "A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T and CARVac-based in vivo expansion to improve treatment of patients with CLDN6+ advanced solid tumors"



Luca Gattinoni

Leibniz Institute for Immunotherapy (LIT)/Germany
 "CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies"




Chiara Bonini

IRCCS Ospedale San Raffaele/Italy
 "Neoantigens beyond SNVs: embracing the full spectrum of antigenic dark matter in tumors"

Meeting report

Berger, AB, Freitag J, Linkenbach S, Merz L, Schork M, Thevissen S, Yildiz I & Beck J CIMT 2022: Report on the 19th Annual Meeting of the Association for Cancer Immunotherapy. Human Vaccines & Immunotherapeutics, DOI: [10.1080/21645515.2022.2124785](https://doi.org/10.1080/21645515.2022.2124785)

CIMT 2022 was made possible by the generous support from our sponsors and donors:



Sponsors and Donors

in 2022



/ CIMT STATISTICS 2022*

TOP 5 countries of attendees

- #1 Germany
- #2 Netherlands
- #3 USA
- #4 Switzerland
- #5 Denmark



Would you visit another CIMT meeting?



Have you attend the meeting on site or via livestream?



How do you judge the general meeting organization?



*based on attendees' questionnaires of the 2022 CIMT Annual Meeting

/ 2022 CIMT POSTER AWARDS

With the generous support of Immatics Biotechnologies, CIMT was able to honor the work of young scientists in each of the six poster categories.

During the poster sessions, the poster jury members evaluated the poster presenters based on the quality and ingenuity of their research, poster design and presentation skills.

⊕ **New Targets & New Leads**

Marit van Elsas, Leiden University Medical Center/The Netherlands
“CD163 tissue-resident macrophages drive primary and secondary cancer immunotherapy resistance”

🎯 **Therapeutic Vaccination**

Ida Olsson, Uppsala University/Strike Pharma/Sweden
and

Aman Mebrahtu, KTH Royal Institute of Technology Stockholm/Strike Pharma/Sweden
“An agonistic CD40 bispecific antibody designed for flexible synthetic peptide-cargo delivery through an affinity interaction, a way to ensure optimal T-cell activation”

⚡ **Improving Immunity**

Matthieu Besneux, Prokarium/UK
“ZH9: a live bacterial immunotherapy that reprograms suppressive macrophages and induces trained immunity”

🧬 **Cellular Therapy**

Miranda H. Meeuwse, Leiden University Medical Center/The Netherlands
“T cell receptor-based targeting of immunoglobulin constant domains for treatment of multiple myeloma ”

🧠 **Tumor Biology & Interaction with the Immune System**

Christian Schmidl, Leibniz Institute for Immunotherapy/Germany
“Integrated single-cell profiling dissects cell-state-specific enhancer landscapes of human tumor-infiltrating T cells”



🧠 **Immunomonitoring**

Simone Blaess, University of Tübingen/Werner Siemens Imaging Center/Germany
“In-vivo T-cell activation kinetics visualized by longitudinal OX40- and CD69-immunoPET during combination cancer immunotherapy”

👥 **Audience Choice**

Valentina Volpin, Regensburg Center for Interventional Immunology (RCI)/Germany
“The serine/threonine kinase CAMK1D confers immune resistance of PD-L1 refractory tumor cells against tumor-reactive cytotoxic T cells”

/ 2022 CIMT TRAVEL | REGISTRATION GRANTS

As in the years before the Corona virus pandemic, CIMT supported young scientists from underrepresented countries with travel awards to offset expenses incurred for travelling to the meeting. CIMT also awarded two grants for livestream viewing to young scientists who were not able to travel to Mainz.

The award winners were:

David Reparaz Pernaut (Spain) • **Ahmet Kürsat Koc** (Turkey) • **Farzaneh Meimandi Parizi** (Iran) • **Sofia Khazan-Kost** (Israel) • **Ayca Yazgan** (free livestream) • **Damla Pehlivan** (free livestream)

Ci3/CIMT Patient Symposium

After the very successful Ci3/CIMT Patient Symposium held in 2021, Ci3 and CIMT worked together with Vision Zero Oncology to organize another online Patient Symposium on cancer immunotherapy. Vision Zero Oncology is a German association that aims to reduce the number of preventable cancer cases to almost zero. Vision Zero is well connected in the cancer community and managed to engage several renowned speakers for the symposium.

The symposium, which was streamed from the Rheingoldhalle Conference Center on May 9, was designed for a German audience, and it featured the following topics: advances in tumor therapy, HPV vaccination, patient competence, and reduction in the number of cancer cases. The audience once again could ask the speakers questions via an online tool. According to a survey held after the event, the audience very much appreciated the opportunity to ask specific questions about their cancer entity and to learn about the latest development in cancer treatment. Around 100 people attended the online event.



EINE INITIATIVE VOM

2022 Summer School

In collaboration with:



UNIVERSITÀ
di VERONA



CIMT ACADEMY OF TRANSLATIONAL CANCER IMMUNOLOGY

After the 2nd Winter School of the Academy had to be cancelled due to the coronavirus pandemic, CIMT was very happy to host the first Summer School in Italy in collaboration with the University of Verona and NIBIT. The three-day event was held September 5-8 at a hotel in a small village east of the city of Verona. Thanks to a generous grant from the University of Verona, CIMT was able to organize a very attractive event and even provide four travel grants. The event gave the participants the opportunity to learn about the latest developments in cancer immunology, to present their own research work, to learn about ways to advance their career in science, as well as to network with senior researchers and other participants. The 24 PhD students and post-docs came from renowned institutions from all over Europe, the US, and the Middle East. CIMT was very pleased that the speakers did not only share their extensive experience in translational cancer research, but also provided a relaxing and welcoming atmosphere in the classroom, at dinner or during the afternoon leisure activities.

Faculty included CIMT President Özlem Türeci, Alberto Mantovani (Istituto Clinico Humanitas/Humanitas University, Milan, Italy), Michael Platten (Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany), Markus Maeurer (Champalimaud Foundation and Botton-Champalimaud Pancreatic Cancer Center, Lisbon, Portugal), Kalijn Bol (Radboud University Medical Center, Nijmegen, The Netherlands), Kim Kortekaas (Leiden University Medical Center, Leiden, The Netherlands), Sine Reker Hadrup (Technical University Denmark, Herlve, Denmark), Maria Rescigno (Humanitas University, Milan, Italy), Vincenzo Bronte (University of Verona, Verona, Italy), Susanna Mandruzzato (Istituto Oncologico Veneto, Padua, Italy), and Christoph Huber (CIMT). The informal setting of the event allowed the participants to learn and network beyond of what is usually possible at larger conferences.



CIMT Academy of Translational Cancer Immunology

CIMT's driving mission is to promote the development of cancer immunotherapy. Fundamental to ensuring the success of this field is the education of the next generation of translational scientists. Given that translational science as a discipline is not yet a component of many graduate schools, we identified an educational gap that CIMT was exceptionally qualified to fill.

The CIMT Academy of Translational Immunology offers a learning and dissemination platform dedicated solely to our developing membership.


CIMT Winter/Summer School for Early Career Scientists

The CIMT Winter/Summer School for Early Career Scientists is the CIMT Academy's flagship event. Via its small size, the Winter/Summer School is designed to offer participants an extraordinary development experience among peers and leaders in a beautiful setting. The relaxed, yet comprehensive program and involvement of supportive leaders in the field provide participants with one-on-one learning and networking opportunities.

Participants gain cutting-edge knowledge of the field via data-driven lectures on the latest cancer immunology/immunotherapy topics as well as insider know-how on academic, clinical, and industrial perspectives from expert faculty. Scientific presentation and discussion skills are addressed by receiving feedback from fellow participants and faculty. Meeting and networking with experienced and early career translational researchers alike are facilitated with the goal to build and encourage collaborations.

Please see www.cimt.eu/academy for more information and future events.


Sixth CRI-ENCI-AACR International Cancer Immunotherapy Conference



After a three-year hiatus, the international CICON meeting collaboration “Translating Science Into Survival” resumed in New York City. From September 28- October 1, 2022, an outstanding roster of speakers presented on all areas of all areas of inquiry in cancer immunology and immunotherapy. As in previous years, the meeting provided an unparalleled opportunity for teaching, learning, and networking among all stakeholders in the field: scientists, clinicians, regulators, drug developers, and patient advocates.

In 2023 the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference will take place in Milan, Italy, September 23-25. The International Cancer Immunotherapy Conference (CICON) is a joint conference series between the Cancer Research Institute (CRI), the European Network for Cancer Immunology (ENCI), and the American Association for Cancer Research (AACR). The first CICON meeting took place in 2015 and alternates between New York City and European location.

The meeting website provides more information at www.cancerimmunotherapyconference.org



Financial Summary

Association for Cancer Immunotherapy CIMT e.V.

BALANCES AS OF DECEMBER 31, 2022*

ASSETS	2022	2021
Fixed assets	4,420	3,685
Current assets	87,698	139,661
Banks	529,417	532,002
Total	621,535	675,348
LIABILITIES	2022	2021
Equity	585,939	642,667
Accruals	36,662	22,557
Liabilities	5,952	10,124
Total	628,553	675,348
	2022	2021
Turnover	684,248	488,814
Other income incl. donation	649	649
Personnel expenses	-149,482	-108,928
Depreciation	-294	-363
Expenses for CIMT meetings & Winter School	-464,993	-212,940
Other expenses	-122,786	-77,719
Income taxes	-14,432	-16,611
Result after taxes	-57,533	73,002

* all figures are in EUR

Addresses Imprint

POSTAL ADDRESS

Association for Cancer Immunotherapy CIMT e.V.

Göttelmannstr. 17
55130 Mainz, Germany
Telephone: +49 (0) 151 - 53 222 559
Website: www.cimt.eu
E-Mail: office@cimt.eu

REGISTER OF ASSOCIATIONS

Amtsgericht Mainz: VR 3783

CONCEPT AND DESIGN

LABOR – Agentur für moderne Kommunikation GmbH

Fischtorplatz 21
55116 Mainz, Germany
Telephone: +49 (0) 6131 - 30 46 76 2
Website: www.labor.digital

TEXTS AND EDITING

Christine Castle
Christiane Wellié-Reeve

PHOTOS

Isabelle Niefer
Andrea Enderlein
Foto Rimbach